Manufacturer record

Affine Formulations Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

2 batches manufactured by Affine Formulations Ltd (Himachal Pradesh) were declared Not of Standard Quality between January 2023 and January 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

2 records linked to Affine Formulations Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
2Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Jan 2023 to Jan 2023

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

2
NSQ batches since 2023
2
Products affected
Assay
Most common failure
Jan 2023
Latest alert

Flagged batches per year

2023 · 2

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Peritoneal Dialysis Solution IP with 2.5% w/v Dextrose PD2206098Mfg 2022-06 · Exp 2024-05 Assay of Calcium, Magnesium and LactateAssay RDTL ChandigarhCDSCO lab Jan 2023
Levocetirizine Hydrochloride Tablets IP (Levocetirizine Tablets) AF-22T619Mfg 2022-08 · Exp 2024-07 DissolutionDissolution RDTL ChandigarhCDSCO lab Jan 2023

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.